Gilead resubmits new HIV drug Lenacapavir marketing application
- Global Surge in Mycoplasma Pneumoniae Infections Sparks Expert Warnings
- Discovery of New Targets for Treating Cancer and Age-Related Diseases
- Why Blood Sugar Levels Increase in Winter?
- Zepbound: Eli Lilly new weight-loss drug 20% cheaper than Wegovy
- US$300K: Compensation Granted as Woman Dies Following COVID-19 Vaccination
- Gut Bacteria Enhance Cancer Immunotherapy: Study Reveals Potential Role of Lactobacillus reuteri
Gilead resubmits new HIV drug Lenacapavir marketing application
- FDA Investigates T-Cell Malignancy Risk in CAR-T Cell Therapy
- WHO Requests More Information from China on Pediatric Clustered Pneumonia
- First Chinese PD-1 Cancer Drug 30 Times More Expensive in U.S. than in China
- Cardiovascular Diseases Linked to COVID-19 Infections
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
Gilead resubmits new HIV drug Lenacapavir marketing application, requiring only two doses per year
On June 27 , Gilead announced that it had resubmitted to the U.S. Food and Drug Administration (FDA) its development of a long-acting HIV-1 capsid inhibitor, Lenacapavir, for the treatment of severe multidrug-resistant (MDR) HIV-1 infection. (HTE) New Drug Application (NDA) for HIV-1 infection in patients .
If eventually approved, Lenacapavir would be the first and only HIV-1 regimen to be administered twice a year.
This time, Gilead resubmitted the NDA for Lenacapavir .
In February 2022 , the FDA issued a Complete Response Letter ( CRL ) questioning the Chemical Manufacturing and Control ( CMC ) issue of the borosilicate glass vial’s compatibility with Lenacapavir injectable solution .
The NDA resubmission contains comprehensive CMC data to support the compatibility of Lenacapavir with alternative vial types made of aluminosilicate glass.
In addition, the NDA is supported by extensive preclinical and early clinical study data and data from the Phase 2/3 CAPELLA study evaluating the antiviral activity of Lenacapavir administered subcutaneously every six months in combination with other antiretroviral drugs For persons with severe treatment experience with multidrug-resistant HIV-1 infection.
Once the NDA is accepted by the FDA , a new Prescription Drug User Fee Act (PDUFA) date will be set.
“Due to resistance to multiple antiretroviral therapies, some people living with HIV have very limited treatment options,” said Jared Baeten , MD, vice president of HIV clinical development at Gilead Sciences . “We are committed to addressing unmet needs and Recognize the urgency of filling critical treatment gaps for patients with multidrug-resistant HIV whose virus is no longer responsive to current treatments.”
Gilead resubmits new HIV drug Lenacapavir marketing application
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
